<DOC>
	<DOCNO>NCT02306915</DOCNO>
	<brief_summary>Cohorts Japanese participant enrol treated prior cohort Caucasian participant sake match . Every effort make match Caucasian Japanese participant cohort basis enrollment . Reasonable effort make maintain balance male female participant within cohort . There replacement participant follow randomization .</brief_summary>
	<brief_title>PK , PD , Safety Tolerability Lipegfilgrastim Healthy Japanese Caucasian Participants</brief_title>
	<detailed_description>Eligible participant admit investigational center confirm eligibility randomize receive single dose 30 , 60 , 100 μg/kg lipegfilgrastim . There 11 visit investigational center study , include screen visit , 1 inpatient period ( Day 4 post-dose ) 9 ambulatory visit . Blood sample PK , PD immunogenicity analysis collect pre-dose specified time point post-dose . A mandatory blood sample pharmacogenetics ( PGx ) collect participant . During study follow safety assessment perform : vital sign measurement , physical examination , record adverse event , clinical laboratory test , urinalysis , safety ECG recording , local tolerability ( injection site reaction ) , overall tolerability , pregnancy testing , spleen sonography , concomitant medication</detailed_description>
	<criteria>Body mass index ( BMI ) ≥18.0 ≤25 kg/m2 . Body weight must ≥ 50 kg ≤ 90 kg . Is good general health determine medical history , physical examination , 12lead electrocardiography ( ECG ) , vital sign clinical laboratory test . Subjects able read , write understand English Japanese ; must able understand requirement study willing comply trial requirement . Female subject childbearing potential must negative serum βhuman chorionic gonadotropin ( βhCG ) test screen negative urine pregnancy test checkin . All subject must either surgically sterile ( female mean documented complete hysterectomy , bilateral oophorectomyor bitubal ligation ; partial hysterectomy sufficient ) , abstinent throughout study , reproductive capacity abstinent , exercise 2 different form highly effective contraception method his/her partner entire study period . Additional inclusion criterion Japanese subject : Subject must nonnaturalized Japanese citizen hold Japanese passport . Subject must have/had 2 Japanese parent 4 Japanese grandparent nonnaturalized Japanese citizen , confirm interview . Subject living outside Japan 10 year few confirm interview . Additional inclusion criterion Caucasian subject : The subject Caucasian , confirm interview his/her parent grandparent Caucasian none Black/African descent , MiddleEastern descent Asian descent . criterion apply , please contact investigator information History hypersensitivity pegfilgrastim , filgrastim , lenograstim , Escherichia coli derived protein , excipients ( glacial acetic acid , sodium hydroxide , sorbitol , polysorbate 20 ) . Prior exposure filgrastim , pegfilgrastim lenograstim granulocyte colony stimulate factor ( GCSFs ) clinical development le 6 month randomization . Findings splenomegaly sonography , define splenic length excess 12.3 cm ( Andrews , 2000 ; Benter et al , 2011 ) clinical judgment . Existence recent history persistent pulmonary infiltrates recent pneumonia , current symptom upper respiratory infection . In case pneumonia , subject may screen 12 week follow cessation antibiotic treatment . criterion apply , please contact investigator information</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Lipegfilgrastim , Lonquex , Japanese Bridging</keyword>
</DOC>